In August 2023, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide licence with the University of Chile for its technology designed as a system for quantification of neutralizing antibodies against SARS-CoV-2. This technology can be used in the facility using heightened control measures similar to biosafety level 2 laboratories.

MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to providing as much detail as possible as to what the developer intends to do with a sublicence.

Key Features
Aim of the Licence To facilitate the worldwide use of technology which allows to detect the presence of neutralising antibodies against SARS-CoV-2.
Products Any product that uses the licensed know-how or material.
Know‐how The University will provide all necessary know-how and materials to the licensees, specified in the licence
Field of use COVID-19
Territory Worldwide. The sublicensee shall not be a commercial entity either incorporated or manufacturing the products in Chile.
Scope of the grant Non-exclusive right to grant sublicences to develop the licensed know how/material into products, and to commercialize licensed products.
  • royalty-free for low and middle-income countries.
  • 3% for high-income countries where the sublicensee has used the licensed technology for the manufacture of the products.
Term 10 years from the Effective Date
Country List